This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.
This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Pharmaceutical companies should look for CDMOs with a proven track record of working with various molecules and pharmaceutical companies.
In the ever-evolving landscape of pharmaceutical research and development, a revolutionary force is reshaping the way we approach drug discovery and repurposing. This force is none other than Artificial Intelligence (AI) and Machine Learning (ML).
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who aren’t insured or are willing to pay cash for their medications.
The pharmaceutical industry has undergone significant changes over the past decade, with a growing trend towards outsourcing key aspects of research, development, and manufacturing to third-party vendors. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48
This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market. Retrieved from [link] Japan Pharmaceutical Manufacturers Association. Freyr Solutions.
Comprehensive ADMET analysis indicated favorable pharmaceutical properties, including oral absorption via the BBB and GI tract. For cholinesterase inhibition, compounds 8 and 13 outperformed Galantamine against AChE, and compound 9 showed the strongest BuChE inhibition.
5(4-Hydroxyphenyl)-2-(N-Phenyl amino)-1,3,4-Oxadiazole (Hppo) can considered as a versatile agent in designing novel pharmaceuticals. Thus, our findings can provide novel and versatile compounds for the development of multidirectional drugs in the pharmaceutical industry.
Why Your Law Firm's Playbook May Be Holding You Back As the pharmaceutical industry continues to evolve at breakneck speed, one thing remains constant: the importance of a robust patent strategy. Read on to discover the Patent Playbook your law firm may not be sharing with you: [link] #patentstrategy #pharmaceuticals #innovation"
Regulatory backing The pharmaceutical industry is often open to innovation in principle, but the demands of regulatory compliance can slow the adoption of emerging technologies – particularly those that challenge conventional trial design.
The pharmaceutical industry is highly dynamic, with frequent filings and updates that require timely access to information[2]. Limited Search Filters While Google Patents offers basic search functionalities, it lacks advanced filters specific to pharmaceuticals. Implications for Pharmaceutical Stakeholders 1.
"Revolutionizing the Pharmaceutical Industry: How AI-Powered Portfolio Management is Changing the Game As the pharmaceutical landscape continues to evolve, companies are under increasing pressure to optimize their portfolios and stay ahead of the competition. link] #pharmaceuticals #portfoliooptimization #AIinpharma"
This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies. Understanding the Pharmaceutical Market Dynamics The pharmaceutical industry is a complex ecosystem where branded drugs and generics coexist, each playing a vital role in patient care and market dynamics.
India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. The country’s pharmaceutical sector has experienced substantial growth over the years, driven by both domestic and international demand for affordable and high-quality medicines.
ABSTRACT Fused pyrimidine scaffolds serve as a flexible and versatile foundational heterocycle in the field of pharmaceutical development. Thienopyrimidines exhibit multifarious features, mainly, this is due to their structural resemblance with purine bases, such as guanine and adenine.
Multimodal language models Generative AI models (GenAI) in the pharmaceutical field have reached the highest level of attention with the Nobel Prizes to Demis Hassabis and John Jumper for AlphaFold, which can predict protein structures. This approach limits the transformative potential of the technology.
In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. “Pharmacognosy is the bridge between traditional medicine and modern pharmaceutical science, offering a treasure trove of potential new drugs waiting to be discovered.”
At DrugBank, we’re dedicated to empowering pharmaceutical researchers with data that drives impactful results. Your Need for Accessible, High-Quality Data—Solved Pharmaceutical research and healthcare innovation demand timely access to comprehensive, up-to-date data. In fact, poor data quality is estimated to cost U.S.
The pharmaceutical industry is known for its complex regulatory environment and lengthy product development processes. One often overlooked aspect of this industry is the potential benefits of abandoned and expired patents.
Multiple deals have been struck by large companies such as Roche and Novartis, suggesting pharmaceutical firms believe degraders have only begun to show their promise.
Patent filings represent one of the most valuable yet underutilized sources of competitive intelligence in the pharmaceutical industry. By systematically monitoring and analyzing these documents…
It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials.
1,2,3 Among a long list of innovations, the lowest hanging fruit for commercialization is the use of microgravity-based crystallization to enhance high-value pharmaceuticals. Pharmaceuticals are among the worlds most valuable materials by weight leading branded drugs, particularly biologics, carry list prices that often exceed $1M per kg.
As the pharmaceutical industry continues to evolve, drug developers encounter new challenges and opportunities in their pursuit of innovation. From adapting to complex new trial designs to embracing cutting-edge technologies, staying ahead requires a deep understanding of the current landscape.
A personal journey to Alltrna Michelle Werner’s career has spanned over 20 years in the pharmaceutical industry, where she developed her expertise in oncology drug development at leading companies such as Bristol Myers Squibb, AstraZeneca, and Novartis.
For small- and medium-sized pharmaceutical companies, outsourcing represents a strategic leap forward, offering a gateway to unparalleled expertise and cutting-edge analytical technologies. Such an approach ensures reliable preclinical toxicology data and supports the transition of innovative therapies from the lab to clinical trials.
This new chapter in the strategic partnership between WuXi Biologics and VISEN Pharmaceuticals underscores a shared commitment to innovation, localization, and improved patient care. VISEN Pharmaceuticals expects to obtain regulatory approval for lonapegsomatropin in China by 2025. Chen said. “By
Mass spectrometry imaging (MSI) enables the direct detection and quantitation of active pharmaceutical ingredients (APIs) and metabolites within tissue sections, making it widely regarded as a promising technique in the field of pharmacology and toxicology.
Based on those findings, and in consultation with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), Asahi Kasei Pharma is moving forward with a focused effort to evaluate the drug’s clinical utility in a broader patient population. Source link
Global Head of Research and Early Development for Cardiovascular, Renal, and Immunology at Bayer’s Pharmaceuticals Division. Our shared commitment is to explore novel technologies and therapeutic targets in various cardiovascular and renal diseases to help deliver new treatment options to patients in need,” said Andrea Haegebarth, Ph.D.,
Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.
He has over 20 years’ experience in biomedical research and pharmaceutical drug discovery. About the author Anirban Datta, Head of Discovery Biology at Verseon International Corporation Anirban Datta PhD is the head of discovery biology at Verseon International Corporation.
Strategic Collaboration with Ionis Pharmaceuticals Salanersen originated from Biogen’s longstanding collaboration with Ionis Pharmaceuticals, Inc. , We are encouraged by the available data and eager to move salanersen into the next stage of development as quickly as possible.” a leader in RNA-targeted therapeutics.
Prior to WuXi AppTec, Dr Li held scientific leadership roles in CROs and pharmaceutical companies in Canada and Japan. Her expertise spans CRO oversight, regulatory strategy and CTD-compliant submissions for INDs and NDAs. She holds a PhD in pharmacology from Japan, and an MD and MSc from China.
In the fast-paced world of pharmaceuticals, negotiations play a pivotal role in shaping the industry’s landscape. Let’s dive into the intricacies of pharmaceutical negotiations, exploring valuable lessons, current trends, and strategies for success.
According to Dr. Kelvin Tan , Chief Medical Affairs Officer at Jazz Pharmaceuticals, the data add to the growing body of evidence supporting sodium reduction as a modifiable risk factor. The new late-breaking data presented by Jazz Pharmaceuticals at SLEEP 2025 solidify Xywav’s position as a cornerstone treatment in narcolepsy management.
AI is influencing all industries, but its impact will be especially strong in pharmaceuticals where it is expected to accelerate drug discovery and, in clinical settings, generate patterns and insights from vast quantities of patient data to enable more personalised treatments.As
In this context, the USP’s mAb reference standards offer pharmaceutical manufacturers a critical benchmark. Through this collaboration, we’re reinforcing our commitment to advancing pharmaceutical quality by making science-based solutions more accessible and adaptable for developers of mAbs and gene therapies.”
The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to streamline the drug development and manufacturing process. CDMOs provide a wide range of services that cater to the diverse needs of pharmaceutical companies, from early-stage development to commercial manufacturing.
Dr. Bock has previously held leadership roles at MD Anderson, Teva Pharmaceuticals, CoGenesys, and Human Genome Sciences. Based in Houston, TX, CTMC was established to accelerate patient access to impactful cell therapies by bridging cell therapy development and manufacturing with MD Andersons clinical trial capabilities.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content